Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies

Conditions

• Head and Neck Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - 70 Years

Healthy Volunteers

Not accepted

Interventions

• Apatinib — DRUG
  Apatinib 500mg qd plus S-1 50mg bid d1-d14/28d cycle

Study Details

This open, single-arm, exploratory study looked at the efficacy and safety of apatinib in combination with S-1 as second-line treatment of advanced head and neck malignancies.

Key Dates

Start date

Oct 16, 2018

Status verified

Oct 2018

Primary completion

Mar 1, 2020

Completion

Sep 1, 2021

Study Design

Enrollment

30 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Apatinib+S-1
  Patients with recurrent/metastatic head and neck malignancies received apatinib plus S-1 as second-line therapy.

Primary Outcome Measure

PFS [ Time Frame: 40 months ]

Central Contacts

• Liu Ping, doctor
  13975157508
  [email protected]
• Liu Bin, doctor
  13973127325
  [email protected]

Related Studies

• Identification and Characterization of Novel Proteins and Genes in Head and Neck Cancer
  Recruiting · Stanford University · Stanford, California
• Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
  Recruiting · Stanford University · Stanford, California
• Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
  Recruiting · Vanderbilt University Medical Center · Nashville, Tennessee
• Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
  Recruiting · University of Colorado, Denver · Aurora, Colorado